|
Statistical data on all aspects of business, industry, economics and
demographics presented in tabular form.
TableBase(TM) contains tables of data relating to companies,
products, industries, brands, markets, countries and demographics
from around the world. The database always includes the table and,
when available, the text from the original article.
The tables are the focus of the database: for added precision each
table has had a title created summarising its content; also,
comprehensive indexing terms are applied to the content of the table
rather than to the original article as a whole. When an original
article contains more than one table, individual documents are
created in BTBL for each one.
Some 90 different industries are included and the database is global
in its coverage. Information in the database covers current year,
historical data, time series and forecasts for:
- demographics
- imports and exports
- industry and product forecasts
- market share
- market size
- market trends
- number of outlets and users
- output and capacity
- price trends
- production and consumption
- rankings
- sales and company forecasts
- shipments
Use BTBL to answer questions like:
- what is the forecast market for take-up of broadband services in
Western Europe to 2007?
- what is the market share and value by sales of foreign drug
companies in Poland?
- what has been the world price for copper over the last 10 years?
- who are the top 25 advertisers in radio and television?
- what is the global capacity forecast for propylene oxide in 2005?
Sources:
Data is derived from privately published statistical annuals, trade
associations, non-profit research groups, government agencies and
international organisations - like the UN and WHO, industry reports
prepared by investment research groups and from the over 900 source
publications from the Business & Industry database (BIDB).
Note that data in the following documents is fabricated.
1 BTBL
AN - Accession number & update
01002013 20031107.
TT - Table title
Global and US pharmaceutical research and development
expenditures in US dollars for 1985, 1990, 1995, 2000 and
2003.
TI - Title
A glimpse of medicines to come.
TA - Annotated title
Total research and development spending by pharmaceutical
companies worldwide will grow 11.5% to $18.9 bil in 2003.
SO - Source
Pharma Business What's in the Pipeline Directory.
p. 3+, August 2003.
TB - Table
Research and development spending
Research and U.S. Research and
development abroad development
1985 $427.5 $1,549.2
1990 $698.9 $3,378.7
1995 $1,617.4 $6,802.9
2000 $3,33.5 $11,874.0
2003 $3,816.0 $15,045.1
Source: Pharmaceutical Research and Manufacturers of
America, Washington
Source:
Pharmaceutical Research & Manufacturers of America.
TX - Text
The focus of researchers and developers is on finding drugs
to fight cancer. They're also interested in treating
diseases of the central nervous system and the heart.
Infections are high on their list, too.
The prescription medicines that will shape the
pharmaceutical industry of the next 10 years are in this
year's pipeline directory.
Of the 2,235 products listed in this directory, 234 products
are awaiting marketing approval in various markets
throughout the world; 437 products are in Phase III clinical
trials; 565 products are in Phase II trials; 324 products
are in Phase I trials; and 523 products are in preclinical
development. Almost 450 companies are involved in developing
or marketing these products.
The products awaiting approval should be launched within a
year or so. The products waiting for regulatory clearance
were developed to treat a host of diseases, including
allergies, cancer, depression, migraine, osteoporosis,
schizophrenia, and ulcers. A review of the products that are
about 10 years away from the market (those in Phase I
clinical trials) reveals a more intense focus on developing
drugs to treat cancer--going beyond brain, breast,
colorectal, non-small cell lung cancer, and prostate cancer
to cervical, gastrointestinal, head and neck, ovarian,
pancreatic, and renal cell cancers (see box on page 6).
Cancer is the most active area of study with 394 products in
development, followed by central nervous system disorders
with 243 products and cardiovascular conditions with 184
products. And 127 products are being developed for the
treatment of infections.
One hundred and two drugs are in development to treat AIDS
and HIV infection and related conditions. Researchers are
working to find new and effective therapies for AIDS, an
area where there is a critical need. Although there are 42
approved medicines for AIDS and AIDS-related ailments, more
effective treatments are still needed for the many afflicted
with this disease. To date, worldwide, about 4.5 million
people have died from AIDS.
photo omitted
Research and development spending
Research and U.S. Research and
development abroad development
1985 $427.5 $1,549.2
1990 $698.9 $3,378.7
1995 $1,617.4 $6,802.9
2000 $3,33.5 $11,874.0
2003 $3,816.0 $15,045.1
Source: Pharmaceutical Research and Manufacturers of
America, Washington
photo omitted
In total, more than 2,200 drugs are being developed by
almost 450 pharmaceutical, biotechnology, and drug delivery
companies. In this second edition of What's in the Pipeline
directory, the editors have compiled these products and
listed them first by their status and then by their
therapeutic category. The editors also compiled a list of
products whose trials were discontinued in the last year.
Additionally, this edition includes a list of the first
products approved in the United States in 1997, the products
approved in the United States in 1996, and the first-time
European approvals of 1996.
Research-based pharmaceutical companies will invest $18.9
billion in research and development in 1997, an 11.5%
increase over 1996. These expenditures include $15.1 billion
spent within the United States by both U.S.-owned and
foreign-owned companies, plus an additional $3.8 billion
spent abroad by U.S.-owned companies.
Research-based companies have more than doubled their
research and development spending since 1990. And these
figures just take into account members of the Pharmaceutical
Research and Manufacturers of America. When all
biotechnology and pharmaceutical companies are considered,
the figure is much higher.
More than one-third of company-financed research and
development in the United States is devoted to evaluation of
promising drug compounds in human clinical trials. Phase I,
Phase II, and III trials account for 30% of research and
development spending. An additional 5% of research and
development spending is allocated to Phase IV clinical
trials, which may occur after the product has received
regulatory approval.
photo omitted
In addition, about 10% of research and development spending
is allocated for manufacturing process development and
quality control functions.
Pharmaceutical companies allocate more than 40% of research
and development to preclinical functions. About 11% of
research and development is spent on synthesizing and
extracting compounds for evaluation. Subsequent biological
screening and pharmacological testing account for 16% of
research and development. Later testing for toxicology and
safety requires about 6% of research and development and
dosage formulation and stability testing requires more than
9%.
Over the past two decades, the percentage of sales allocated
research and development has increased from 11% in 1980 to
more than 21% in 1997. Meanwhile, the average research and
development to sales ratio for industries in the United
States is less than 4%. Based on corporate tax data compiled
by Standard & Poor's, pharmaceutical manufacturers invest a
higher percentage of sales in research and development than
high-tech industries such as electronic, aerospace, office
equipment (including computers) and automobile.
The success rate of compounds is diminished as they get
closer to market -- for every 5,000 to 10,000 discovered,
250 progress to preclinical development and Phase I clinical
trials; just five progress to Phase II and Phase III
clinical trials; and one of these will be filed for
marketing approval. Discovery research takes about
four years, preclinical testing takes about four years,
Phase I clinical trials take about two years, Phase II
clinical trials take about three years, Phase III clinical
trials take about four years, and regulatory review takes
about one to two years.
photo omitted
The cost of developing drugs is estimated by government
economists at $359 million. This estimate, however, captures
the final cost for drugs that entered clinical trials during
the late 1970s. A precise projection for what it may cost to
develop a drug today is difficult. Industry sources place
the number near the $500 million mark.
Notes and methodology
Information presented in this directory of drugs in the
pipeline was gathered from pharmaceutical, biotechnology,
and drug delivery companies, industry sources, the Internet,
annual reports, Form 10-Ks, and internal resources of Engel
Publishing Partners. For a product to be included in this
directory, that product must be in development (preclinical
trials through Phase III) or awaiting approval for the
treatment of human diseases and disorders. Drug delivery
technologies are only included when they have been applied
to a therapeutic agent.
The directory is organized by the products' phase of
development. The products are presented in alphabetical
order within their status. Products awaiting marketing
approval are presented first (page 8), followed by products
in Phase III clinical trials (page 20), Phase II/III
clinical trials (page 38), Phase II clinical trials (page
40), Phase I/II clinical trials (page 58), Phase I trials
(page 62), and preclinical development (page 72). Products
that are in various phases of development for different
indications or formulations are cross-referenced within the
appropriate section.
This year's directory has been expanded to include
information, when available, about a product's class,
administration, region of development, and marketing status
in the major markets throughout the world.
The editors have tried to determine which company has
marketing rights in which region. When known, the division
within the company that will be responsible for the
marketing of the product is listed. For companies that are
seeking development and marketing partners, the marketer is
listed as "To be determined."
For gene therapies, the editors provide information, when
available, about the gene and the technology or vector being
studied.
The products listed within the preclinical development
section include products that are undergoing animal studies
and in the research stage.
Products are presented by their trade name. When a trade
name is not available, the chemical or code name is used.
For many products in preclinical or early development
stages, only the class may be known and provided in this
directory.
This directory also presents the products in development by
therapeutic category (page 88). The categories are presented
in alphabetical order, and the products are listed in chart
format in alphabetical order within their category.
For the first time this year, the editors have included a
listing of the companies, their addresses, telephone numbers
and facsimile numbers (when available) that are developing
and plan to market these products (see page 136).
What's coming out in one year; in ten years
Products coming to market within one year will be for ...
* ache
* adhesion prevention
* allergies
* Alzheimer's disease
* amyotrophic lateral sclerosis
* angina
* anxiety
* arrhythmias
* asthma
* bacterial infections
* benign prostatic hypertrophy
* cancers
brain
breast
colorectal
Kaposi's sarcoma
non-Hodgkin's lymphoma
non-small cell lung
prostate
* cholesterol
* congestive heart failure
* contraception
* Crohn's disease
* deep vein thrombosis
* dementia
* depression
* diabetic foot ulcers
* diabetic gastroparesis
* diabetic neuropathy
* diphtheria, tetanus, pertussis
* epilepsy
* erectile dysfunction
* fungal infections
* gastritis
* genital warts
* growth hormone deficiency
* hemophilia
* hepatitis B; hepatitis C
* herpes
* HIV infections
* hyperglycemia
* hypertension
* hypogonadism in men
* imaging
* incontinence
* infections
* infertility
* influenza
* ischemic stroke
* menopausal symptoms
* menstrual disorders
* migraine
* myocardial infarction
* narcolepsy
* neutropenia
* nocturnal heartburn
* non-insulin-dependent diabetes
* obesity
* osteoporosis
* pancreatitis
* panic disorder
* Parkinson's disease
* Pneumocystis carinii pneumonia
* psoriasis
* rabies
* respiratory distress syndrome
* schizophrenia
* sleep induction
* smoking cessation
* specific pain
* ulcers
* wound healing
Products coming to market within 10 years will be for...
* acne
* AIDS-related dementia
* AIDS vaccination
* allergies
* Alzheimer's disease
* amyotrophic lateral sclerosis
* angina
* anxiety
* asthma
* bacterial infections
* benign prostatic hypertrophy
* burns
* cachexia
* cancers
B-cell lymphoma
brain tumor
cervical
chemotherapy sensitization
colorectal
gastrointestinal
head and neck
Kaposi's sarcoma
leukemia
lung
lymphomas
malignant melanoma
non-Hodgkin's lymphoran
non-small cell lung
ovarian
pancreatic
prostate
renal cell
* cholesterol
* coronary artery bypass graft
* coronary ischemia
* cystic fibrosis
* cytomegalovirus infection
* deep vein thrombosis
* depression
* diabetic neuropathy
* emphysema
* epilepsy
* glaucoma
* hemorrhagic shock
* hepatitis B; hepatitis C
* herpes
* HIV infection
* Huntington's disease
* hypertension
* hypogonadism in men
* imaging
* incontinence
* infections
* influenza
* menopausal symptoms
* migraine
* multidrug-resistant cancer
* multiple sclerosis
* myocardial infarction
* neoplastic meningitis
* neuroblastoma
* non-insulin-dependent diabetes
* organ transplant rejection
* osteoporosis
* Parkinson's disease
* Pneumocystis carinii pneumonia
* psoriasis
* pulmonary hypertension
* red blood cell stimulation
* respiratory distress syndrome
* rheumatoid arthritis
* schizophrenia
* septic shock
* severe pain
* sleep induction
* stroke
* tuberculosis.
CC - US SIC codes
US SIC codes
283400 Pharmaceutical-preparations
IR - Industry terms
Pharmaceutical.
DC - Concept terms
Time-Series; All-product-and-service-information; R-and-D-
expenditures.
CN - Country & region
North America (NOAX); United States (USA); World (WOR).
DD - Data types
Business.
PT - Publication type
Journal.
AT - Article type
Time-Series.
LG - -Language
English.
DT - Publication date
20030811.
YR - Publication year
1997
PU - Publisher
Engel Publishing Partners, United States.
AV - Availability
Fulltext.
LE - Length
15,395 Characters, approximately 9 PC screens.
CP - Copyright statement
Copyright 2003 Engel Publishing Partners
Image: True
Document Fulfillment: True
CD-ROM: All
Local Redistribution: All
Local Archive: All.
2 BTBL
AN - Accession number & update
01001870 20031107.
TT - Table title
Sales of slimming and supplementary nutrition, by seven
countries, in national currencies, for 2000, estimated for
2005.
TI - Title
UK slimming sales set to leap 42pc by 2005.
TA - Annotated title
UK slimming & supplementary nutrition sales will rise 42%
to UKPd738mil by 2005; Japan is now the world's largest
market, worth $5,214mil, followed by US at $4,635mil.
SO - Source
Chemist & Druggist.
no. 6104, p. 37, September 20, 2003, ISSN: 0009-3033.
TB - Table
Slimming and supplementary nutrition sales, millions*
2000 2005
France 3,439 3,400
Italy** 924 1,255
UK 518 738
US 4,635 5,911
Germany 2,290 2,325
Spain 36,253 36,358
Japan** 562 651
* National currencies at constant 1996 prices
** Billions
Source: Euromonitor
Source:
Euromonitor.
TX - Text
UK slimming and supplementary nutrition sales are expected
to jump 42 per cent to Pd738 million by 2005, reports
Euromonitor.
While some quarters claim the UK is becoming a nation of
'fatties', many consumers are still interested in healthy
living and are willing to buy supplements to help them diet.
The market researcher's report, 'Slimming and Supplement
Nutrition', states that the UK supplements market grew 9.6
per cent in real termslast year - much higher than the rate
in the US, Italy and Japan, which were the only other key
markets to experience real growth.
UK consumers will buy more supplements because they want to
"age gracefully". The market was the second biggest in
Europe last year. However, that still left it about half the
size of that in Germany, which topped DM2,290m.
Japan is the world's largest market - worth $5,214m -
followed by the US at $4,635m.
Sports nutrition and meal replacements (other than slimming
products) are the biggest sectors in the UK slimming and
supplementary nutrition market. Slimming aids is the third
largest, as it is in the US, Germany and Japan.
Pharmacies and drug stores accounted for the bulk of
vitamin, mineral and dietary supplement sales last year in
most of the key markets. This is mainly because many of the
OTC products were once Prescription Only and are therefore
bought habitually at pharmacies.
Euromonitor's 'Slimming and Supplement Nutrition' is priced
at Pd2,250. Tel: 020 7251 1105.
Slimming and supplementary nutrition sales, millions*
2000 2005
France 3,439 3,400
Italy** 924 1,255
UK 518 738
US 4,635 5,911
Germany 2,290 2,325
Spain 36,253 36,358
Japan** 562 651
* National currencies at constant 1996 prices
** Billions
Source: Euromonitor.
CC - US SIC codes
US SIC codes
283483 Nutritional-supplements
IR - Industry terms
Pharmaceutical.
DC - Concept terms
All-market-information; Industry-forecasts; Market-size;
Sales.
CN - Country & region
European-Union (EUCX); France (FRA); Germany (GER); Italy
(ITA); Japan (JPN); North-America (NOAX); Pacific Rim
(PARX); Spain (SPA); Southern-and-Eastern-Asia (SSAX);
United-Kingdom (UNK); United States (USA); Western-Europe
(WEEX).
DD - Data types
Business.
PT - Publication type
Journal.
LG - Language
English.
DT - Publication date
20030920.
YR - Publication year
2003
PU - Publisher
Miller-Freeman plc, United Kingdom.
AV - Availability
Fulltext.
LE - Length
6,218 Characters, approximately 4 PC screens.
CP - Copyright statement
Copyright 1997 Miller-Freeman plc
Image: True
Document Fulfillment: True
CD-ROM: All
Local Redistribution: All
Local Archive: All.
3 BTBL
AN - Accession number & update
01002385 20031107.
TT - Table title
Global magnesium primary production by country in metric
tons from 1996 through 2005 revised estimated.
TI - Title
WORLD PRIMARY PRODUCTION OF MAGNESIUM BY COUNTRY.
SO - Source
Metal Statistics Nonferrous Edition.
p. 198, 2003.
TB - Table
WORLD PRIMARY PRODUCTION OF MAGNESIUM BY COUNTRY (1)(2)
Production of metallic magnesium of the world. Through 2005,
in tons of 2,000 pounds; from 1996, in metric tons.
Compiled by the U.S. Geological Survey.
1996 1997 1998 1999 2000
Brazil (e) 4,356 5,488 5,865 6,200 8,700
Canada 5,100 8,800 7,600 7,200 25,300
China (e) 3,000 3,000 3,200 3,600 5,900
France 13,361 13,601 13,776 14,600 14,000
Italy 12,417 7,626 5,436 5,469 5,730
Japan 8,116 8,180 9,012 8,381 12,800
Kazakhstan (3) (e) NA NA NA NA NA
Norway 56,522 56,907 50,317 49,827 48,200
Russia (3) (e) NA NA NA NA NA
Serbia & Montenegro (4) NA NA NA NA NA
Ukraine (e) NA NA NA NA NA
U.S.S.R. (e)(5) 89,000 90,000 91,000 91,000 88,000
U.S. 125,639 124,396 141,983 152,066 139,000
Yugoslavia (4)(6) 4,897 5,932 6,176 6,105 5,790
Total 322,408 323,930 334,365 344,448 354,000
2001r 2002r 2003r 2004r
Brazil (e) 7,800 7,300 9,700 9,700
Canada 35,500(3 25,800 23,000 28,900
China (e) 8,600 10,600 11,800 24,000
France 14,050e 13,660 10,982 12,280
Italy 3,919 1,211 ... e ... e
Japan 11,559 7,119 7,471 3,412
Kazakhstan (3) (e) NA 3,000 2,000 ...
Norway 44,322 30,404 27,300 27,635
Russia (3) (e) NA 40,000 30,000 35,400
Serbia & Montenegro (4) NA 4,055 0e 2,000e
Ukraine (e) NA 15,000 14,900 12,000
U.S.S.R. (e)(5) 80,000 NA NA NA
U.S. 131,000 137,000 132,000 128,000
Yugoslavia (4)(6) 5,360 NA NA NA
Total 342,000 295,000 269,000 284,000
2005e
Brazil (e) 9,700
Canada 48,100
China (e) 40,000
France 12,000
Italy ...
Japan ... (3)
Kazakhstan (3) (e) ...
Norway 35,000
Russia (3) (e) 37,500
Serbia & Montenegro (4) 2,000
Ukraine (e) 13,000
U.S.S.R. (e)(5) NA
U.S. 142,000(3)
Yugoslavia (4)(6) NA
Total 339,000
r-Revised.
e-Estimated.
NA Not applicable.
(1) World totals, U.S. data and estimated data are rounded
to three significant digits; may not add to totals shown.
(2) Includes data available through 8/15/2005.
(3) Reported figure.
(4) Includes secondary.
(5) All production in Yugoslavia for 2001 came from Serbia
and Montenegro.
(6) Dissolved 12/2001.
(7) Dissolved 4/2002.
Source:
US Geological Survey.
CC - US SIC codes
US SIC codes
333935 Magnesium-refining
IR - Industry terms
Metals.
DC - Concept terms
Time-Series; All-market-information; Output.
CN - Country & region
Brazil (BRA); Canada (CDA); Canada (CDAX); China (CHI);
Commonwealth-of-Independent-States (CISX); Eastern-Europe
(EAEX); European-Union (EUCX); France (FRA); Italy (ITA);
Japan (JPN); Kazakhstan (KAZ); Latin-America (LAMX);
Northern-and-Central-Asia (NCAX); North-America (NOAX);
Norway (NOR); Pacific-Rim (PARX); Russia (RUS); Scandinavia
(SCAX); South-and-Central-America (SOCX); Southerna-and-
Eastern-Asia (SSAX); Ukraine (UKR); United-States (USA);
Western-Europe (WEEX); World (WOR); Yugoslavia (YUG).
DD - Data types
Business.
PT - Publication type
Report.
AT - Article type
Time-Series.
LG - Language
English.
DT - Publication date
20030000.
YR - Publication year
2003
PU - Publisher
American Metal Market, Chilton Publications, United States.
AV - Availability
NoText.
LE - Length
9,668 Characters, approximately 6 PC screens.
CP - Copyright statement
Copyright 1997 Capital Cities Media, Inc.
Image: True
Document Fulfillment: True
CD-ROM: All
Local Redistribution: All
Local Archive: All.
Label/description Example
AN Accession number 1_: 01002013.AN.
& update - see Limit options -
TT Table title 2_: PHARMACEUTICAL WITH
RESEARCH ADJ
DEVELOPMENT.TT.
TI Title - display only -
TA Annotated title - display only -
SO Source (includes SJ AS)* 3_: SO=PHARMA-BUSINESS$
SJ Source journal 4_: SJ=PHARMA-BUSINESS$
or 5_: PHARMA ADJ BUSINESS.SJ.
AS Additional source information
ISSN= ISSN number 6_: ISSN=0009-3033
TB Table (includes DS) 7_: RESEARCH WITH
SPENDING.TB.
DS Data source* 8_: DS=PHARMACEUTICAL-
RESEARCH$
TX Text - display only -
DE Descriptors
(includes CO PA CC IR DC AC CN DD) 9_: UNITED-STATES$.DE.
CO Company name* 10_: ABBEY ADJ
NATIONAL.CO.
or 11_: MIDLAND-BANK$.CO.
PA Parent company (search only)* - searchable as per CO -
CC US SIC codes and text* 12_: 283400.CC.
add # for broader retrieval 13_: 28#
14_: PHARMACEUTICAL ADJ
PREPARATIONS.CC.
IR Industry terms* 15_: TELECOM ADJ
SERVICES.IR.
DC Concept terms* 16_: TIME ADJ SERIES.DC.
AC Advertising and marketing terms* 17_: DISTRIBUTION ADJ
CHANNELS.AC.
CN Country and region* 18_: UNITED ADJ
STATES.CN.
Middle East as a region: 19_: MIE.CN.
Middle East as a region and/or
all constituent countries: 20_: MIEX.CN.
Relating specifically to the USA 21_: US=US
DD Data types 22_: MACRO ADJ
ECONOMIC.DD.
TN Tradenames 23_: TROJAN ADJ
MAGNUM.TN.
PT Publication type 24_: PT=FACT-SHEET
..ROOT PT= for a list
AT Article type 25_: AT=TIME-SERIES
..ROOT AT= for a list
LG Language 26_: LG=ENGLISH
DT Publication date - see Limit options -
DATE= Publication date 27_: DATE=19970826
MONTH= Publication month 28_: MONTH=199708
YR Publication year - see Limit options -
YEAR= Publication year 29_: YEAR=1997
PU Publisher - display only -
XR Cross references 30_: 01217702.XR.
AV Availability of original text
FT= Available in full text 31_: FT=Y
AB= Available as abstracts only 32_: AB=Y
No text available 33_: NOTEXT.AV.
- see also Notes below -
LE Length - display only -
CP Copyright statement - display only -
(*) The ROOT command is especially useful in these paragraphs to
establish, for example, how a company or country name appears
in the database.
1_: EXPORTS WITH PALM
ADJ OIL.TT.
DATE Publication date YYYYMMDD 2_: ..L 1 DATE>19970726
MONTH Publication month YYYYMM 3_: ..L 1 MONTH=199712
YEAR Publication year YYYY 4_: ..L 1 YEAR LT 1998
UDATE Update date YYYYMMDD 5_: ..L 1 UDATE GT
19971127
UMONTH Update month YYYYMM 6_: ..L 1 UMONTH WL.
By paragraph - table title, table _: ..P TT, TB 1-10
SHORT AN TT SJ DS DT YR AV
MEDIUM AN TT TI TA SO (SJ AS) TB TN DT YR AV
LONG AN TT TI TA SO (SJ AS) TB (CO CC IR DC AC CN DD) DE TN
DT YR AV
ALL AN TT TI TA SO (SJ AS) TB DS TX (CO* CC IR DC AC CN DD)
DE TN PT AT LG DT YR PU XR AV LE CP
FREE AN TT DS (CO CC IR DC AC CN DD) DE PT AT LG YR PU AV LE CP
_ :..P LONG 2,3-5
For a clear indication of document content, use the following print
command (all FREE paragraphs):
_: ..P AN, TT, DS, YR 1-5
Refer to the BASE database (search as BASE-BTBL) for details of how
to set this as your default USER print option.
TT - Table title:
Each table has had a title created for unambiguous retrieval of
information. This is the only searchable 'title' paragraph in the
database.
PA/CO - Parent company names:
If the parent company name is known, it will be displayed within
pointed brackets - <...> - directly following its subsidiary company
name in the CO paragraph. To distinguish parents from subsidiaries,
the parent name is searchable as .PA. - e.g.:
1_: TIME-WARNER$.PA.
DE - Descriptor terms:
Full lists of Industry (IR), Concept (DC), Advertising and marketing
(AC) and Country and region (CN) terms are available in the BASE
database - search as BASE-BTBL.
AV - Availability
Between October 2001 and September 2002, a number of documents have
been assigned the wrong availability flag. This error has been
corrected for documents loaded into the database after September
2002.
Guides:
For a complete guide to the TableBase database, search BASE-BTBL in
BASE.
The Gale Group databases are provided "as is" without warranty of
any kind. Neither The Gale Group nor any of its data suppliers make
any warranty whatsoever as to the accuracy or completeness of any of
the databases or the results to be obtained from using the
information contained therein and neither The Gale Group nor any of
its data suppliers shall be responsible for any claims attributable
to errors, omissions or other inaccuracies in the information
contained in any of its databases. The entire risk as to the results
and performance of any database is assumed by the user of that
database. Further, neither The Gale Group nor any of its data
suppliers make any representations or warranties either express or
implied, with respect to any of the databases, including, but not
limited to the quality, performance, merchantability, or fitness for
a particular purpose of any database or any information contained
therein. In no event shall The Gale Group or any of its data
suppliers be liable for direct, indirect, special, incidental or
consequential damages arising out of the use of or inability to use
any database or for any loss or damage of any nature caused to any
person as a result of the use of the database. Material contained in
any database may not be duplicated or redistributed without the
prior written consent of The Gale Group.
Back to the Datasheet Index Page
© 2010 Dialog LLC All Rights Reserved
|